JWH-161

From Wikipedia, the free encyclopedia
Jump to: navigation, search
JWH-161
JWH-161 structure.png
Systematic (IUPAC) name
(4aR,13bR)-2,5,5-trimethyl-8-pentyl-3,4,4a,5,8,13b-hexahydroisochromeno[3,4-b]carbazol-13-ol
Clinical data
Legal status
?
Identifiers
ATC code ?
PubChem CID 10431286
ChemSpider 8606713
Chemical data
Formula C27H33NO2 
Mol. mass 403.555 g/mol
 YesY (what is this?)  (verify)

JWH-161 is a cannabinoid derivative that was designed by Dr John W. Huffman's team as a hybrid between the dibenzopyran "classical" cannabinoid drugs and the novel indole derivatives, in an attempt to unravel the differences in their binding modes to the CB1 receptor. While retaining structural elements from both families, JWH-161 has a CB1 Ki of 19.0nM, although it was found to be slightly weaker than THC in animal tests.[1]

References[edit]

  1. ^ Huffman JW, Padgett LW (2005). "Recent developments in the medicinal chemistry of cannabimimetic indoles, pyrroles and indenes". Current Medicinal Chemistry 12 (12): 1395–411. doi:10.2174/0929867054020864. PMID 15974991.